Skip to main content
. 2017 Jan 7;17:45. doi: 10.1186/s12879-016-2106-x

Fig. 1.

Fig. 1

Patient flow. Patients included in intent-to-treat and as-treated analyses of sustained virologic response at four weeks after the end of treatment (SVR4) and at 12 weeks after the end of treatment (SVR12)